Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from the first cohort of its clinical proof of concept trial of AZP–3601, which the company is developing as a potential treatment for hypoparathyroidism. The data demonstrate that AZP–3601 was well–tolerated and daily administration to patients enabled discontinuation of the standard of care while mean serum calcium was maintained within the target range. Detailed data from cohort 1 will be presented at an upcoming medical conference later this year and full data is expected in fall 2022.
